Sanofi Invests €1.3 Billion in Next-Generation Insulin Facility in Frankfurt

1. Investment Amount: Sanofi is investing €1.3 billion ($1.4 billion) in a new insulin production facility.
2. Location: The facility will be located at Sanofi's BioCampus in Frankfurt Höchst, Germany.
3. Purpose: The new plant aims to secure long-term insulin supply for people with diabetes worldwide.
4. Completion Date: The facility is slated for completion by 2029.
5. Impact: This investment is expected to bolster Sanofi's capabilities in producing next-generation insulin products.